624 related articles for article (PubMed ID: 26212868)
1. Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C.
Pineda JA; Núñez-Torres R; Téllez F; Mancebo M; García F; Merchante N; Pérez-Pérez M; Neukam K; Macías J; Real LM;
J Infect; 2015 Nov; 71(5):571-7. PubMed ID: 26212868
[TBL] [Abstract][Full Text] [Related]
2. Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfected individuals.
Berenguer J; Gil-Martin Á; Jarrin I; Montes ML; Domínguez L; Aldámiz-Echevarría T; Téllez MJ; Santos I; Troya J; Losa JE; Serrano R; De Guzmán MT; Calvo MJ; González-García JJ;
AIDS; 2019 Mar; 33(4):685-689. PubMed ID: 30829744
[TBL] [Abstract][Full Text] [Related]
3. Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.
Simmons B; Saleem J; Hill A; Riley RD; Cooke GS
Clin Infect Dis; 2016 Mar; 62(6):683-694. PubMed ID: 26787172
[TBL] [Abstract][Full Text] [Related]
4. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?
Pradat P; Pugliese P; Poizot-Martin I; Valantin MA; Cuzin L; Reynes J; Billaud E; Huleux T; Bani-Sadr F; Rey D; Frésard A; Jacomet C; Duvivier C; Cheret A; Hustache-Mathieu L; Hoen B; Cabié A; Cotte L;
J Infect; 2017 Sep; 75(3):234-241. PubMed ID: 28579302
[TBL] [Abstract][Full Text] [Related]
5. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
[TBL] [Abstract][Full Text] [Related]
6. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies.
Sacks-Davis R; van Santen DK; Boyd A; Young J; Stewart A; Doyle JS; Rauch A; Mugglin C; Klein M; van der Valk M; Smit C; Jarrin I; Berenguer J; Lacombe K; Requena MB; Wittkop L; Leleux O; Bonnet F; Salmon D; Matthews GV; Guy R; Martin NK; Spelman T; Prins M; Stoove M; Hellard M;
Lancet HIV; 2024 Feb; 11(2):e106-e116. PubMed ID: 38224708
[TBL] [Abstract][Full Text] [Related]
7. Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam.
Grady BP; Vanhommerig JW; Schinkel J; Weegink CJ; Bruisten SM; Lindenburg CE; Prins M
Eur J Gastroenterol Hepatol; 2012 Nov; 24(11):1302-7. PubMed ID: 22825643
[TBL] [Abstract][Full Text] [Related]
8. The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis.
Huang P; Wang Y; Yue M; Ge Z; Xia X; Jeyarajan AJ; Holmes JA; Yu R; Zhu C; Yang S; Lin W; Chung RT
Liver Int; 2021 Oct; 41(10):2341-2357. PubMed ID: 34051040
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C reinfection after sustained virological response.
Midgard H; Bjøro B; Mæland A; Konopski Z; Kileng H; Damås JK; Paulsen J; Heggelund L; Sandvei PK; Ringstad JO; Karlsen LN; Stene-Johansen K; Pettersson JH; Dorenberg DH; Dalgard O
J Hepatol; 2016 May; 64(5):1020-1026. PubMed ID: 26780289
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV.
Young J; Rossi C; Gill J; Walmsley S; Cooper C; Cox J; Martel-Laferriere V; Conway B; Pick N; Vachon ML; Klein MB;
Clin Infect Dis; 2017 May; 64(9):1154-1162. PubMed ID: 28199495
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus reinfection among prisoners with sustained virological response after treatment for chronic hepatitis C.
Marco A; Esteban JI; Solé C; da Silva A; Ortiz J; Roget M; Sarriera C; Teixidó N; Guerrero RA; Caylà JA
J Hepatol; 2013 Jul; 59(1):45-51. PubMed ID: 23523577
[TBL] [Abstract][Full Text] [Related]
12. Reinfection in a large cohort of prison inmates with sustained virological response after treatment of chronic hepatitis C in Catalonia (Spain), 2002-2016.
Marco A; Guerrero RA; Vergara M; Gallego C; Solé C; Planella R; Vaz ME; Teixidó N; Sastre A; Touzón C; da Silva A; Almada G; Ruíz A; Caylà JA; Turu E
Int J Drug Policy; 2019 Oct; 72():189-194. PubMed ID: 31160156
[TBL] [Abstract][Full Text] [Related]
13. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.
Islam N; Krajden M; Shoveller J; Gustafson P; Gilbert M; Buxton JA; Wong J; Tyndall MW; Janjua NZ;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):200-210. PubMed ID: 28404135
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C reinfection with protease inhibitor-resistant hepatitis C virus in an HIV-coinfected MSM.
Yilmaz GR; Boesecke C; Schwarze-Zander C; Rockstroh JK
Liver Int; 2020 Jan; 40(1):47-50. PubMed ID: 31612570
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs.
Weir A; McLeod A; Innes H; Valerio H; Aspinall EJ; Goldberg DJ; Barclay ST; Dillon JF; Fox R; Fraser A; Hayes PC; Kennedy N; Mills PR; Stanley AJ; Aitken C; Gunson R; Templeton K; Hunt A; McIntyre P; Hutchinson SJ
Drug Alcohol Depend; 2016 Aug; 165():53-60. PubMed ID: 27268294
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
[TBL] [Abstract][Full Text] [Related]
18. The rate of hepatitis C reinfection in Canadians coinfected with HIV and its implications for national elimination.
Young J; Wang S; Lanièce Delaunay C; Cooper CL; Cox J; Gill MJ; Hull M; Walmsley S; Wong A; Klein MB;
Int J Drug Policy; 2023 Apr; 114():103981. PubMed ID: 36893502
[TBL] [Abstract][Full Text] [Related]
19. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ
J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387
[TBL] [Abstract][Full Text] [Related]
20. Determining the frequency and characteristics of Hepatitis C reinfections in North East England.
Askar S; Jelley R; McQue K; Allsop C; McCullough F; Miller C; Taha Y; Masson S; McPherson S
J Viral Hepat; 2022 Aug; 29(8):685-690. PubMed ID: 35643915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
